Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

The FDA has granted breakthrough therapy designation (BTD) to JBS-003 (18F-fluoromisonidazole [FMISO]), a first-in-class hypoxia PET tracer, for the identification of tumor hypoxia to guide de-escalated radiation therapy in patients with HPV-positive oropharyngeal carcinoma (OPC), according to a news release from the developer, Juniper Biosciences.¹ JBS-003 is under evaluation in a randomized, double-blind phase 3 trial (NCT06563479) comparing FMISO-guided de-escalated radiation with standard-of-care radiation in HPV-positive OPC.

What does the JBS-003 breakthrough therapy designation cover?

BTD is reserved by the FDA for programs addressing serious or life-threatening conditions where preliminary clinical evidence indicates the potential for substantial improvement over available therapy. The designation provides the drug’s developer with intensive FDA guidance on an efficient development program, organizational commitment from senior agency leadership, and eligibility for rolling and priority review. According to the release, the designation was supported by the body of clinical evidence generated for FMISO-guided radiation de-escalation, spanning the foundational investigator-led hypoxia imaging experience at MSK and the ongoing clinical program.

“We are excited that the FDA has granted breakthrough therapy designation, and we look forward to completing this phase 3 trial and generating the pivotal evidence needed to support potential FDA approval,” stated Nancy Y. Lee, MD, FASTRO, radiation oncologist and service chief of Head and Neck Oncology and Proton Therapy at Memorial Sloan Kettering Cancer Center, in the press release.¹

What unmet need does JBS-003 address in HPV-positive OPC?

The current standard of care for HPV-positive OPC delivers a uniform dose of 70 Gy of radiation regardless of individual tumor biology. This approach frequently produces severe and permanent toxicities, including osteoradionecrosis (the death of the jawbone requiring surgical removal), significant weight loss necessitating long-term feeding tubes, swallowing dysfunction, and sustained quality-of-life impairment. Because a meaningful proportion of patients with HPV-positive OPC harbor well-oxygenated tumors that may respond adequately to lower doses, the standard regimen subjects many patients to radiation injury that may not be necessary for disease control.

How does JBS-003 identify candidates for reduced radiation?

JBS-003 is a PET radiotracer that binds selectively to hypoxic tumor cells. Administered during a course of chemoradiation, FMISO-PET imaging identifies which patients harbor radiation-resistant hypoxic tumor regions. Patients with non-hypoxic scans are eligible for a de-escalated dose of 30 Gy. Patients with positive FMISO scans, indicating a hypoxic, radiation-resistant tumor environment, continue with the standard high-dose course. This biomarker-directed strategy individualizes radiation intensity based on each patient’s underlying tumor biology.

What is the design of the JBS-003 phase 3 trial in oropharyngeal cancer?

The ongoing phase 3 trial, is a randomized, double-blind study evaluating FMISO-selected de-escalated radiation vs standard radiation in unselected patients with HPV-positive OPC.² Patients underwent a FMISO-PET scan at week 2 of treatment, typically day 10, within a window of days 8 through 10 of radiation, and those with non-hypoxic results are eligible for the 30 Gy de-escalated arm. The trial is expected to reach primary completion in early 2028.

“This designation is a powerful validation of what precision imaging can do for these patients. Using FMISO PET imaging, we can visualize the specific hypoxic signatures of a tumor to maintain aggressive control where it’s needed, while safely reducing radiation doses for patients with well-oxygenated tissue. The FDA has now recognized that this approach may represent a substantial improvement over the current standard of care,” stated Alex Agnoletto, chief executive officer and co-founder of Juniper Biosciences, in the press release.¹

References

1. Juniper’s JBS-003 (F-MISO) program receives FDA breakthrough therapy designation, advancing a first-in-class hypoxia tracer enabling radiation de-escalation in HPV-positive head and neck cancer. News release. Juniper Biosciences. September 1, 2026. Accessed September 1, 2026. https://tinyurl.com/2h7hbxn9
2. Phase III randomized and double-blinded trial of de-escalated radiation in FMISO PET-selected good risk versus standard of care radiation in unselected HPV positive oropharyngeal cancer. ClinicalTrials.gov. Updated July 28, 2026. Accessed September 1, 2026. https://tinyurl.com/mtja2ct8